SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics reported a GAAP net loss of $0.15 per share for Q3…

Outlook Therapeutics, Inc. · PRESS-RELEASE filed Aug 14, 2026 at 07:15 ET

At the news

MIXEDIMPACT 7/10

PRESS-RELEASE filed Aug 14, 2026 at 07:15 ET

Outlook Therapeutics reported a GAAP net loss of $0.15 per share for Q3 FY2026, significantly missing the consensus estimate of -$0.07. Revenue was negligible at $9K, down from $1.5M a year ago, as the company is pre-commercial launch in the U.S. The filing is dominated by the upcoming U.S. launch of LYTENAVA (wet AMD), with management projecting over $500M in peak annual sales by 2030. However, the severe cash crunch ($11.2M at quarter-end) and subsequent dilutive $51.1M public offering in August 2026 temper the bullish launch narrative, creating a mixed picture where a transformative product launch is offset by immediate financial fragility and shareholder dilution.

  • GAAP EPS of -$0.15 missed consensus of -$0.07 by 113.3%.
  • Revenue was just $9K, down from $1.5M in the prior-year quarter.
  • Cash and cash equivalents were $11.2M as of June 30, 2026, with a going-concern risk noted in the prior 8-K.
  • Subsequent to quarter-end, the company raised ~$51.1M in net proceeds from a dilutive public offering of 55.6M shares and warrants.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access